Huntington National Bank lessened its holdings in shares of Humana Inc (NYSE:HUM) by 0.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,825 shares of the insurance provider’s stock after selling 43 shares during the period. Huntington National Bank’s holdings in Humana were worth $3,034,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Nomura Asset Management Co. Ltd. raised its position in shares of Humana by 2.8% during the 1st quarter. Nomura Asset Management Co. Ltd. now owns 46,924 shares of the insurance provider’s stock worth $14,735,000 after acquiring an additional 1,288 shares in the last quarter. Engineers Gate Manager LP purchased a new position in Humana during the 1st quarter worth approximately $455,000. State of Alaska Department of Revenue grew its stake in Humana by 8.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 32,214 shares of the insurance provider’s stock worth $12,490,000 after buying an additional 2,427 shares during the last quarter. IBM Retirement Fund grew its stake in Humana by 51.0% during the 1st quarter. IBM Retirement Fund now owns 3,493 shares of the insurance provider’s stock worth $1,097,000 after buying an additional 1,179 shares during the last quarter. Finally, Strs Ohio grew its stake in Humana by 156.6% during the 1st quarter. Strs Ohio now owns 154,943 shares of the insurance provider’s stock worth $48,655,000 after buying an additional 94,571 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.
HUM has been the topic of a number of research reports. Cowen restated a “market perform” rating and set a $410.00 price target on shares of Humana in a research note on Tuesday, June 16th. They noted that the move was a valuation call. Cantor Fitzgerald raised their price target on Humana from $405.00 to $410.00 in a research note on Wednesday, June 17th. Oppenheimer lifted their target price on Humana from $400.00 to $425.00 and gave the company an “outperform” rating in a research note on Thursday, April 30th. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating and set a $396.00 target price on the stock. in a research note on Friday, April 17th. Finally, Morgan Stanley lifted their target price on Humana from $375.00 to $500.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $414.80.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $5.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.84 by $0.56. The firm had revenue of $18.94 billion for the quarter, compared to the consensus estimate of $18.49 billion. Humana had a return on equity of 21.02% and a net margin of 3.86%. The company’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same period in the previous year, the business earned $4.48 earnings per share. On average, equities research analysts anticipate that Humana Inc will post 18.74 EPS for the current fiscal year.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Read More: What are economic reports?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.